Idiopathic Pulmonary Fibrosis

"Idiopathic Pulmonary Fibrosis" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

A common interstitial lung disease of unknown etiology, usually occurring between 50-70 years of age. Clinically, it is characterized by an insidious onset of breathlessness with exertion and a nonproductive cough, leading to progressive DYSPNEA. Pathological features show scant interstitial inflammation, patchy collagen fibrosis, prominent fibroblast proliferation foci, and microscopic honeycomb change.

Descriptor ID	D054990
MeSH Number(s)	C08.381.483.487.500 C08.381.765.500
Concept/Terms	Idiopathic Pulmonary Fibrosis Idiopathic Pulmonary Fibrosis Idiopathic Pulmonary Fibroses Pulmonary Fibroses, Idiopathic Familial Idiopathic Pulmonary Fibrosis Fibrocystic Pulmonary Dysplasia Dysplasia, Fibrocystic Pulmonary Dysplasias, Fibrocystic Pulmonary Fibrocystic Pulmonary Dysplasias Pulmonary Dysplasia, Fibrocystic Pulmonary Dysplasias, Fibrocystic Fibrosing Alveolitis, Cryptogenic Hamman-Rich Disease Disease, Hamman-Rich Diseases, Hamman-Rich Hamman Rich Disease Hamman-Rich Diseases Interstitial Pneumonitis, Usual Interstitial Pneumonitides, Usual Pneumonitides, Usual Interstitial Pneumonitis, Usual Interstitial Usual Interstitial Pneumonitides Usual Interstitial Pneumonitis Pulmonary Fibrosis, Idiopathic Usual Interstitial Pneumonia Interstitial Pneumonia, Usual Interstitial Pneumonias, Usual Usual Interstitial Pneumonias Idiopathic Fibrosing Alveolitis, Chronic Form Cryptogenic Fibrosing Alveolitis Cryptogenic Fibrosing Alveolitides Fibrosing Alveolitides, Cryptogenic Idiopathic Pulmonary Fibrosis, Familial

Below are MeSH descriptors whose meaning is more general than "Idiopathic Pulmonary Fibrosis".

Diseases [C]
Respiratory Tract Diseases [C08]
Lung Diseases [C08.381]
Lung Diseases, Interstitial [C08.381.483]
Idiopathic Interstitial Pneumonias [C08.381.483.487]
Idiopathic Pulmonary Fibrosis [C08.381.483.487.500]
Pulmonary Fibrosis [C08.381.765]
Idiopathic Pulmonary Fibrosis [C08.381.765.500]

Below are MeSH descriptors whose meaning is related to "Idiopathic Pulmonary Fibrosis".

Below are MeSH descriptors whose meaning is more specific than "Idiopathic Pulmonary Fibrosis".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Idiopathic Pulmonary Fibrosis" by people in this website by year, and whether "Idiopathic Pulmonary Fibrosis" was a major or minor topic of these publications.

Bar chart showing 161 publications over 19 distinct years, with a maximum of 18 publications in 2022

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2008	1	0	1
2009	1	1	2
2010	3	0	3
2011	4	0	4
2012	6	0	6
2013	10	0	10
2014	9	0	9
2015	7	0	7
2016	9	2	11
2017	15	0	15
2018	6	0	6
2019	14	0	14
2020	6	0	6
2021	9	0	9
2022	18	0	18
2023	14	0	14
2024	14	1	15
2025	4	2	6
2026	5	0	5

Below are the most recent publications written about "Idiopathic Pulmonary Fibrosis" by people in Profiles.

Kim JS, Receveur B, Zhang D, Ma SF, Huang Y, McGroder C, Putman RK, Podolanczuk AJ, Rotter JI, Rich SS, Flaherty KR, Lee JS, Lasky JA, Raghu G, Murray S, Spino C, Martinez FJ, Oh A, Lynch DA, Humphries SM, Adegunsoye A, Oldham JM, Hunninghake GM, Garcia CK, Taub M, Mathias RA, Cho MH, Barr RG, Noth I, Mychaleckyj JC, Manichaikul A, Newton CA. Performance of age-adjusted whole genome sequencing telomere length in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2026 Oct 01; 212(10):2445-2454.

View in: PubMed
Kim JS, Loe A, Ma SF, Ranjan P, Lipinski JH, Mikhail SG, Gurczynski SJ, Zhou X, Huffnagle GB, Downward JE, Metcalf JD, Falkowski N, Stringer KA, Dickson RP, Huang Y, Moore BB, Martinez FJ, Murray S, Noth I, O'Dwyer DN. Gut microbiota associate with disease severity and survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2026 Oct 01; 212(10):2455-2466.

View in: PubMed
Khor YH, Luppi F, Adegunsoye A, Collins BF, Farrand E, Montesi SB, Newton CA, Cottin V, Johannson KA, Kaul B, Kolb M, Kreuter M, Molyneaux PL, Wijsenbeek MS, Antoniou K, Behr J, Bendstrup E, Collard HR, Corte TJ, Drake WP, Ferrara G, Hariri LP, Hogaboam CM, Jenkins RG, Kaminski N, Kazerooni EA, Keane MP, Kondoh Y, Lee JS, Luo F, Maher TM, Martinez FJ, Moodley Y, Richeldi L, Sebastiani M, Sime PJ, Stowasser S, Tomassetti S, Wells A, Ryerson CJ, Podolanczuk AJ. Acute exacerbation in fibrotic interstitial lung disease: an international working group report. Am J Respir Crit Care Med. 2026 Oct 01; 212(10):2358-2385.

View in: PubMed
Oldham JM, Azuma A, Kreuter M, Maher TM, Martinez FJ, Richeldi L, Valenzuela C, Wijsenbeek MS, Liu Y, Zisa D, Zoz DF, Cottin V. Nerandomilast in idiopathic pulmonary fibrosis: data from the whole follow-up period of the FIBRONEER-IPF trial. Am J Respir Crit Care Med. 2026 May 01; 212(5):972-980.

View in: PubMed
Konkol SB, Huang Y, Ma SF, Humphries SM, Lynch DA, Paul T, Malik N, Strickland E, Mannem H, Oldham JM, Adegunsoye A, Newton CA, Oh A, Martinez F, Sperling AI, Kim JS, Noth I. The Role of Matrix Metalloproteinase 12 in Distinguishing Idiopathic Pulmonary Fibrosis From Fibrotic Hypersensitivity Pneumonitis. Chest. 2026 Jul; 170(1):157-168.

View in: PubMed
Wuyts WA, Richeldi L, Assassi S, Azuma A, Cottin V, Hoffmann-Vold AM, Kreuter M, Oldham JM, Martinez FJ, Valenzuela C, Wijsenbeek MS, Kanakapura M, James A, Weimann G, Drzewuski C, Coeck C, Maher TM. Design of an open-label extension trial of nerandomilast (BI 1015550) in patients with idiopathic pulmonary fibrosis and progressive pulmonary fibrosis (FIBRONEER™-ON). BMC Pulm Med. 2025 Dec 04; 26(1):10.

View in: PubMed
Kim JS, Pugashetti J, Ma SF, Huang Y, Podolanczuk AJ, Lynch DA, Oh A, Mychaleckyj J, Manichaikul A, Rich S, Chua F, Adams TM, Flaherty KR, Lee JS, Lasky JA, Raghu G, Murray S, Spino C, Martinez FJ, Noth I, Humphries SM, Adegunsoye A, Molyneaux PL, Oldham JM, Newton CA. Associations of interstitial lung disease subtype and CT pattern with lung function and survival. Thorax. 2025 11 14; 80(12):927-934.

View in: PubMed
Alqalyoobi S, Smith JA, Maddali MV, Pugashetti JV, Newton CA, Kim JS, Linderholm AL, Chen CH, Ma SF, Bose S, Murray S, Adegunsoye A, Strek ME, Garcia CK, Wolters PJ, Martinez FJ, Noth I, Oldham JM. Proteomic Biomarkers of Survival in Non-Idiopathic Pulmonary Fibrosis Interstitial Lung Disease. Am J Respir Crit Care Med. 2025 08; 211(8):1452-1462.

View in: PubMed
Richeldi L, Azuma A, Cottin V, Kreuter M, Maher TM, Martinez FJ, Oldham JM, Valenzuela C, Clerisme-Beaty E, Gordat M, Wachtlin D, Liu Y, Schlecker C, Stowasser S, Zoz DF, Wijsenbeek MS. Nerandomilast in Patients with Idiopathic Pulmonary Fibrosis. N Engl J Med. 2025 Jun 12; 392(22):2193-2202.

View in: PubMed
Alonso-González A, Jáspez D, Lorenzo-Salazar JM, Ma SF, Strickland E, Mychaleckyj J, Kim JS, Huang Y, Adegunsoye A, Oldham JM, Stewart I, Molyneaux PL, Maher TM, Wain LV, Allen RJ, Gisli Jenkins R, Kropski JA, Yaspan B, Blackwell TS, Zhang D, Garcia CK, Martinez FJ, Noth I, Flores C. Rare variants and survival of patients with idiopathic pulmonary fibrosis: analysis of a multicentre, observational cohort study with independent validation. Lancet Respir Med. 2025 Jun; 13(6):495-504.

View in: PubMed

People

Explore

Similar Concepts

Top Journals